Cargando…

COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia

Patients with chronic lymphocyticleukemia (CLL) typically have innate/adaptive immune system dysregulation, thus the protective effect of coronavirus disease 2019 (COVID-19) vaccination remains uncertain. This prospective review evaluates vaccination response in these patients, including seropositiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shadman, Mazyar, Liu, Catherine, Eakle, Katherine, Hiew, Hwai J., Biondo, Juliana M.L., Ghia, Paolo, Mato, Anthony R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771252/ https://www.ncbi.nlm.nih.gov/pubmed/36570695 http://dx.doi.org/10.1097/HS9.0000000000000811

Ejemplares similares

How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic
por: Rossi, Davide, et al.
Publicado: (2020)

Improving Outcomes for Patients With Chronic Lymphocytic Leukemia
por: Shadman, Mazyar, et al.
Publicado: (2020)

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia
por: Eichhorst, Barbara, et al.
Publicado: (2020)

The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study
por: Mato, Anthony R., et al.
Publicado: (2020)

Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion
por: Tam, Constantine S., et al.
Publicado: (2020)

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia
por: Eyre, Toby A., et al.
Publicado: (2020)

Vaccinations in CLL: implications for COVID-19
por: Shadman, Mazyar, et al.
Publicado: (2021)

Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia
por: Ujjani, Chaitra, et al.
Publicado: (2022)

Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration
por: Stephens, Deborah M., et al.
Publicado: (2020)

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2021)

Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations
por: Baliakas, Panagiotis, et al.
Publicado: (2022)

Novel-agent combination therapies in chronic lymphocytic leukemia: the law of relative contributions
por: Mato, Anthony R., et al.
Publicado: (2022)

Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2019)

All in the family: back-to-back kinase inhibitors for the treatment of chronic lymphocytic leukemia
por: Thompson, Meghan C., et al.
Publicado: (2021)

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience
por: Shadman, Mazyar, et al.
Publicado: (2019)

Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data
por: Isaac, Krista, et al.
Publicado: (2020)

Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
por: Lopedote, Paolo, et al.
Publicado: (2023)

Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications
por: Wu, Shang-Ju, et al.
Publicado: (2017)

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
por: Campo, Elias, et al.
Publicado: (2018)

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
por: Herishanu, Yair, et al.
Publicado: (2021)

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
por: Seymour, John F., et al.
Publicado: (2023)

Practical approach to management of chronic lymphocytic leukemia
por: Smolej, Lukáš, et al.
Publicado: (2015)

Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia
por: Herishanu, Yair, et al.
Publicado: (2022)

BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia
por: Fiorcari, Stefania, et al.
Publicado: (2020)

Assessing Patients’ Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece
por: Karamanidou, Christina, et al.
Publicado: (2021)

Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia
por: McMahon, Kaylin M., et al.
Publicado: (2017)

Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing
por: Davi, Frédéric, et al.
Publicado: (2020)

A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib
por: Mato, Anthony R., et al.
Publicado: (2022)

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies
por: Sharman, Jeffrey P., et al.
Publicado: (2022)

Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
por: Rhodes, Joanna M, et al.
Publicado: (2021)

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
por: Byrd, John C., et al.
Publicado: (2021)

P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY
por: Munir, Talha, et al.
Publicado: (2023)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study
por: Woyach, Jennifer A., et al.
Publicado: (2023)

P643: CUMULATIVE REVIEW OF HEART FAILURE WITH ACALABRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA USING DATA FROM CLINICAL TRIALS AND POST-MARKETING EXPERIENCE
por: Ghia, Paolo, et al.
Publicado: (2023)

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022)

Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia
por: Schwaederlé, M, et al.
Publicado: (2013)

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
por: Hillmen, Peter, et al.
Publicado: (2023)

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2020)

Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient
por: Hill, Joshua A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p0cu77v13tuhcfqkh6lk89t82e